



AgX100® I-125 Device

Instructions for Use



Do not reuse



Caution



Do not use if package
damaged



Do not resterilize

Rx Only

Caution, Federal (USA)
law restricts this device
to sale by or on the
order of a licensed
physician



Non-sterile



Sterilized using
irradiation



Sterilized using
ethylene oxide



Sterilized using
steam



Device
Manufacturer



Caution:
Radioactive
material



Catalog number



Serial Number



Batch code /
Production identifier



MR Conditional



Use by



RESTRICTIONS ON USE

General

AgX100® seed devices and accessories should be used by physicians who are qualified by training and experience in the safe use and handling of radionuclide brachytherapy sources and whose experience and training has been approved by the appropriate government authorities authorized to license the use of radioactive materials.

AgX100® seed device and accessories should be used in those facilities that have been approved by the appropriate government authorities authorized to license the use of radioactive materials.

Caution should be used when handling the seeds. Direct contact with the AgX100® seed devices should be avoided; the use of forceps or tweezers is recommended.

DO NOT re-sterilize or reprocess the AgX100® seed device.

CAUTION: Implant Needles - Using the stylet with excessive force to manipulate a lodged seed may damage the seed. Needles are not intended to penetrate bone. If resistance is encountered, verify needle position. Do not push into bone as this may cause the needle to bend or break. Replace needle if cannula or tip is damaged.

RADIATION

The 27-35 keV photons of I-125 are substantially absorbed by any high Z material but exhibit desirable penetration in tissue. The half-value layer (HVL) of lead for I-125 is 0.025 mm; the HVL of tissue is 20.0 mm. Exposure can be reduced by 99.9% with a thin sheet of lead (0.25 mm).

Personnel monitoring is required. Dosimetry monitors, such as TLD devices, should be used to monitor hand and whole-body exposure. During preparation of the source device and implantation procedures, all practical steps should be taken to keep exposure as low as reasonably achievable (ALARA). Limiting exposure time, increasing distance, careful planning of the administration procedure, and use of shielded barriers should be considered in meeting this goal.¹⁻³ The Site Radiation Safety Officer should be consulted regarding specific local requirements. Perform a radiation survey on all components upon completion of the seed implant.

In-VIVO CHARACTERISTICS

Clinical efficacy results from the interaction between the emitted ionizing radiation of the I-125 source and the tissue being treated. Titanium encapsulation provides good biocompatibility. Total photon transmission after accounting for attenuation resulting from the titanium capsule and the internal components is approximately 50%.

MRI Safety Information



Non-clinical testing has demonstrated that AgX100® seed is MR-Conditional.

A patient with this device can be scanned safely immediately after implantation under the following conditions:

- Static magnetic field: 3.0-Tesla and 1.5-Tesla
- Maximum spatial gradient magnetic field of 4000-Gauss/cm (40-T/m), or less
- Maximum MR system reported, whole body averaged specific absorption rate (SAR) of 4-W/kg (First Level Controlled Operating Mode) per pulse sequence

MRI-Related Heating and Artifact Information:

Under the scan conditions defined above, the AgX100® seed is expected to produce a maximum temperature rise of less than 3.0°C after 15 minutes of continuous scanning, per pulse sequence.

In non-clinical testing, the image artifact caused by the AgX100® seed extended approximately 2mm from the implant when imaged using a gradient echo pulse sequence and a 3-Tesla MR system.

SOURCE RECEIPT AND STORAGE

Records of receipt, storage, and disposal of AgX100® seed devices should be maintained in accordance with government regulatory policies. Products should be strictly controlled and stored in a secured area. Any discrepancies in seed count must be reported immediately to Theragenics® Customer Service. -

- AgX100® seed devices should remain in the sterile package until ready to use.
- Sterile needles should remain sealed in the sterile package until ready to use.
- Refer to the product label for expiration date.

DISPOSAL

Seeds

When disposal is indicated, AgX100® seed devices should be transferred to an authorized radioactive waste disposal agency. AgX100® should be disposed of with applicable laws and regulations.

Packaging

CAUTION: Handle and dispose radioactive material, needles, accessories, shielding and packaging, in accordance with applicable laws and regulations

WARNINGS AND PRECAUTIONS

A WARNING indicates the potential for death, serious injury, or other serious adverse events due to use or misuse of the device.

AgX100® Seed Devices

AgX100® seeds contain radioactive material.

- DO NOT reuse- Single use only.
- DO NOT re-sterilize.
- DO NOT use if sterile package is damaged.
- DO NOT use a damaged seed. If a seed is damaged or broken, contact your Radiation Safety Office and initiate containment and decontamination in accordance with your facility's radiation safety procedures.
- DO NOT expose implanted seeds to therapeutic levels of ultrasound energy as the device may inadvertently concentrate the ultrasound field and cause harm.
- AgX100® seeds should never be handled roughly or forced into any implant accessory e.g. cartridge or needle. Such force may damage the wall of the seed, potentially causing release of I-125 into the environment or tissues surrounding an implanted seed.

C20™ and Mick® Cartridges

- DO NOT handle cartridges by the spring-loaded plunger.
- DO NOT overtighten the cartridge shield cover.
- DO NOT use force on seeds or cartridges.
- DO NOT force cartridges into applicator.
- DO NOT forcibly remove cartridges from applicator.

Customized preloaded needle kits

A customized preloaded needle kit is a prescription device and must not be used or substituted for anyone other than the patient for whom it has been prescribed.

CAUTIONS

A CAUTION indicates the potential to damage the device as a result of use or misuse of the device.

INDICATIONS for USE

The AgX100® seed device is indicated to treat localized, unresectable tumors with low to moderate radio sensitivity. Tumors may be recurrent or residual following external beam radiation or excision of primary tumor.

AVAILABLE SOURCE STRENGTH RANGE

Source strength is based on the corrected NIST 1999 WAFAC standard, implemented August 16, 2010. Because of the inherent uncertainty in I-125 seed calibration, some seeds within a given lot may fall outside a specific range. The uncertainty of the Air Kerma Strength for AgX100® is approximately ± 7%.

The amount of radioactivity from I-125 seeds required for a treatment depends on the tumor volume, the previous radiation history of the tumor site, and whether external beam radiation will be used in conjunction with the brachytherapy treatment. Established practice should be used for the calculation of the amount of radioactivity to be implanted, the placement of sources within the tissue, and the evaluation of radiation dose distribution achieved.⁴⁻⁸

Dose calculations should account for the anisotropic dose distribution around each I-125 source as with other brachytherapy sources.⁶⁻⁷ Appropriate parameters should be included for planning

PRODUCT DESCRIPTIONS

AgX100®

The AgX100® seed consists of a laser welded titanium capsule containing I-125 adsorbed onto a silver rod. (Figure 1.)




Figure 1: AgX100® Model

Seed Magazines -

Theragenics offers three seed magazines compatible with the Mick® applicator as listed below.

1. Theragenics Vertical Seed Magazine and C20™ magazine has a 20-seed capacity with integrated radiation shielding and seed counter.
2. Mick® Shielded Magazine has a 15-seed capacity.

- AnchorSeed® is a polymer coated seed also offered in a 15-seed magazine. Available only for USA.

Stranded and Custom Loaded Products

- TheraLoad® consists of a variable number of seeds and spacers custom loaded into an 18-gauge brachytherapy needle. The maximum length of configured components may not exceed 7.0 cm.
- TheraSleeve® consists of a variable number of seeds and spacers contained in a bioabsorbable sleeve and custom loaded into an 18-gauge brachytherapy needle. The maximum length of configured components may not exceed 7.0 cm.
- TheraStrand® consists of a variable number of seeds and spacers contained in bioabsorbable suture and custom loaded into an 18-gauge brachytherapy needle. All TheraStrand® configurations begin and end with a 2.75 mm spacer. The maximum length of configured components is 6.5 cm.
- TheraStrand® RT - Loose TheraStrand®- is packaged as a 20-strand capacity shielded container.
- AnchorLoad® contains loose AnchorSeed® and spacers, max length 7.0 cm.

The stiffened suture material used for TheraStrand® and the bioabsorbable sleeve used for TheraSleeve® stabilize the seeds in the treated tissue to provide desired dosimetry and minimize seed movement during delivery/insertion, and help to prevent seed migration.⁹⁻¹⁰ Both materials are biocompatible and are commonly used in medical devices. The spacers used in custom loaded product configurations are made from the same material as the suture.

Needles/ Strand Specifications

- The components are supplied in standard 18-gauge brachytherapy needle.
- The needles contain a bone wax plug that is 5 mm long.
- The bioabsorbable suture and spacers are made of 90/10 (glycolide/L-lactide), for which absorption occurs in 56-70 days.
- The bioabsorbable sleeve is made of 20/80 (glycolide/L-lactide), for which absorption occurs in 140-180 days.
- The bioabsorbable strand polymer is made of polydioxanone, for which absorption occurs in 182-238 days.

PRODUCT SPECIFICATIONS

Source Limitations

It is possible through rough handling (abrasion, incision, etc.), high temperatures, or crushing that an AgX100® device could rupture and leak. If this happens, contact your facility Radiation Safety Officer. The area should be closed off immediately and personnel limited to avoid radioactive contamination. The damaged device should be placed in a sealed container and the area should be decontaminated.

Source Characteristics/Dosimetry

I-125 has a half-life of 59.43 days and decays by electron capture with the emission of characteristic photons and electrons. The titanium walls of the AgX100® device absorbs the electrons. The principal photon emissions are 35.49, 31.71, 30.98, 27.472, and 27.202 keV. The I-125 is adsorbed onto a silver rod as silver iodide. Table 1 shows the decay of I-125. A dosimetric characterization of AgX100® - including Monte Carlo⁴ and experimental⁵ studies were conducted in accordance with AAPM Task Group 43 update (TG43U1).⁶

Table 1: Decay of Iodine-125

Day	Decay Factor								
0	1.000	16	0.830	32	0.689	48	0.571	64	0.474
1	0.988	17	0.820	33	0.681	49	0.565	65	0.469
2	0.977	18	0.811	34	0.673	50	0.558	66	0.463
3	0.966	19	0.801	35	0.665	51	0.552	67	0.458
4	0.954	20	0.792	36	0.657	52	0.545	68	0.452
5	0.943	21	0.783	37	0.650	53	0.539	69	0.447
6	0.932	22	0.774	38	0.642	54	0.533	70	0.442
7	0.922	23	0.765	39	0.635	55	0.527	71	0.437
8	0.911	24	0.756	40	0.627	56	0.520	72	0.432
9	0.900	25	0.747	41	0.620	57	0.514	73	0.427
10	0.890	26	0.738	42	0.613	58	0.508	74	0.422
11	0.880	27	0.730	43	0.606	59	0.503	75	0.417
12	0.869	28	0.721	44	0.599	60	0.497	76	0.412
13	0.859	29	0.713	45	0.592	61	0.491	77	0.407
14	0.849	30	0.705	46	0.585	62	0.485	78	0.403
15	0.839	31	0.697	47	0.578	63	0.480	79	0.398

Calibration

The AgX100® I-125 device is calibrated by direct comparison against a standard source of the same model that has been calibrated by the National Institute of Standards and Technology (NIST) for air kerma strength. The resulting calibration is reported in air kerma strength ($\mu\text{Gy m}^{-2} \text{h}^{-1}$, also defined as U) as well as Apparent Activity (mCi).

Apparent activity refers to the radiation output and not the contained activity. This output quantity is calculated to 12:00 noon ET (Eastern Time) on the given reference date.

Source Output Verification

A Sealed Source Calibration Certificate is provided with every order. The seeds are 100% assayed and assigned to inventory ranges. The Sealed Source Calibration Certificate identifies the

calibration information for each order based on the original assay/inventory range. If you request either 10% or 100% independent assay, an additional Sealed Source Calibration Certificate, including assay results, is provided. A digital image is also provided for custom loaded needle orders. For further verification, a radiograph is provided with every order. Extra loose seeds or calibrated seeds can be provided for independent measurement.

DIRECTIONS FOR USE

TheraStrand® RT (Real Time)

- Open the shipping container and review documentation to verify order contents.
- Remove the sterile container from the lead pig.
- Carefully inspect the sterile container – Do not use if container or Tyvek lid are damaged.
- Peel back the lid and remove the shielded insert to the sterile field, utilizing ALARA practices.
- Using - sterile tweezers to grasp the protruding end of a strand.
- Remove the strand and transfer directly to a sterile brachytherapy needle or to a sterile cutting surface for further processing.
- Repeat steps 1-6 until all strands have been removed from the shielded insert.

Note: In accordance with ALARA principles, it is recommended that strands remain in the shielded insert until ready to process.

Custom Loaded Needles

- Open the shipping container and review documentation to verify order contents.
- Ensure that the Needle Configuration Plan (Form F1007) provided is consistent with the treatment plan. Contact Customer Service if there are discrepancies.
- Open the inner shipper and remove the sterile package(s).
- Carefully inspect the sterile package(s) – Do not use if package or Tyvek lid are damaged.
- Peel to open the sterile package. Remove the foam liner and remove the inner tray to the sterile field.
- During placement of a pre-loaded needle product, ensure the needle hub is pulled fully against the stylet prior to removal from the gland. Pre-loaded products should remain in the sterile container until ready for use.
NOTE: If you need to radiograph your order, remove the bottom cover by separating the snap locks and replace upon completion.
- Take care to avoid contamination when opening the sterile package, TheraLoad®, TheraSleeve®, and TheraStrand® devices may not be resterilized.
- The needle tray is shielded and can be used in either a horizontal or vertical position.
NOTE: Refer also to the Tray Set Up Guide for visual set up instructions.
- To use horizontally:
 - Remove the top cover (unshielded portion, covering the needle stylets) by separating the snap locks.
 - Fold the upper half of the tray underneath the needles and lay flat on the sterile work surface to dispense.
- To use vertically, the top cover is used as a tray base:
 - Repeat the steps above and place the folded needle tray into the tray base. The tray base should be oriented with the three circular stops forward, and the two triangular stops to the rear.
 - Using your thumb and forefinger, engage the butterfly clips on both sides.
NOTE – Use of the butterfly clips provides extra stability to the upright needles but is not required.
- Upon removing needles for use, ensure the stylet lock is secure and carry needles in a horizontal or “tip up” position to avoid loss of seeds in the event that the needle plug has become displaced during shipment.
- Remove stylet lock from needle hub and begin seed placement.

Loose Seeds and Seeds in Magazines

- If you have purchased sterile AgX100® in vials or magazines, aseptic practices should be followed when loading the seeds into a standard 18-gauge brachytherapy needle. Take care not to damage seeds during loading.
- Insert a sterile magazine into your Mick® Applicator and proceed with the implant procedure.
- To open C20™ or Mick® magazine - grasp the magazine body and hold in an upright position.
 - To open a C20™ or Mick® magazine, unscrew the magazine cover and lift off.
 - Remove seeds with fine point sterile tweezers using ALARA practices
- To open the vertical seed magazine (VSM), rotate the cover counterclockwise past the notch until the tab is in the open position. Remove the cover using gentle upward pressure
 - Remove seeds with fine point tweezers using ALARA practices.
 - To replace the VSM cover: position the plunger paddle into the magazine body.
 - Align the open position of the magazine cover with the tab on the magazine body and press the cover into place. Rotate the cover clockwise past the notch until it locks.

STERILIZATION

If you have purchased non-sterile products, sterilize as directed below.

CAUTION: DO NOT use sterilization methods or parameters other than those listed below.

- Before using an autoclave ensure there are drain screens, traps or some other means to prevent loss of seeds through the drain.
- For cylindrical pigs (vial and Mick® magazines): Remove the lid from the lead pig. Loosen the cap of the glass vial for sterilizing loose seeds.
- For rectangular pigs (20 Seed Magazines): Open the lead pig and remove the Tyvek lid from the cup. Replace the pig lid, being sure not to obstruct the vent holes. Wrap the pig.

Validated Parameters for User Sterilization

Table 2: Steam Sterilization

Product Configuration	Cycle	Temperature	Minimum Exposure Time	Drying / Cooling Time
Seeds in vial	Gravity displacement	132° C (270°F)	15 minutes	Drying Time: 0 minutes Cooling Time: 0 minutes
	Prevacuum (flash)	132° C (270°F)	3 minutes (3 preconditioning pulses)	Drying Time: 0 minutes Cooling Time: 0 minutes
Seed Magazine in plastic cup	Prevacuum (flash)	132° C (270°F)	5 minutes (3 preconditioning pulses)	Drying Time: 0 minutes Cooling Time: 0 minutes
Seeds in MICK® Magazines in plastic cup	Gravity displacement	132° C (270°F)	30 minutes	Drying Time: 0 minutes Cooling Time: 0 minutes
	Prevacuum (flash)	132° C (270°F)	5 minutes (3 preconditioning pulses)	Drying Time: 0 minutes Cooling Time: 0 minutes
Seeds in C20 Flatpack	Gravity displacement	121° C (250°F)	24 minutes at 15 psig	Drying Time: 0 minutes Cooling Time: 0 minutes
	Prevacuum (flash)	132° C (270°F)	4 minutes at 27 psig	Drying Time: 0 minutes Cooling Time: 0 minutes

Table 3: Ethylene Oxide Sterilization

Product Configuration	Temperature	Humidity	EtO Concentration	Minimum Exposure Time	Heated Aeration
Seeds in vial	55 ± 2° C	70 ± 5 %RH	725 ± 25 mg/L	2 hours	12 hours at 55 ± 2° C
Seeds in MICK® Magazines	55 ± 2° C	70 ± 5 %RH	725 ± 25 mg/L	2 hours	12 hours at 55 ± 2° C

ADVERSE EFFECTS

WARNING: A correlation between fistula formation and rectal anterior wall biopsy has been reported and is therefore a relative contraindication in these patients.

Adverse effects: Associated with low dose rate prostate brachytherapy implants are: -

- Urinary toxicity: haematuria, perineal bruising and pain, lower urinary tract symptoms (LUTS – such as dysuria, urinary urgency, frequency and nocturia), cystitis, urethritis, superficial urethral necrosis, urinary retention, urinary stricture, bladder neck contracture, urinary incontinence.¹¹⁻¹⁴
- Rectal toxicity: Diarrhea, constipation, anal incontinence/urgency, proctitis, rectal bleeding, rectal stricture, rectal ulcer/rectal fistula.¹⁴ Fistula formation has been described following anterior wall biopsy of the rectum in patients who have been treated with low dose rate brachytherapy.¹⁵⁻¹⁷ Therefore anterior wall biopsy of the rectum should be avoided in these patients. Erectile and sexual function toxicity: Haematospermia, a decline in erectile function is common after brachytherapy with recovery to baseline function returning from 3 months to 5 years after therapy.¹⁸ There are sporadic reports in the literature of paternity after brachytherapy with no evidence of birth anomalies, however usual practice is to recommend sperm banking prior to the procedure if subsequent fertility is a concern.¹⁹

Adverse effects: Associated with temporary ocular plaque brachytherapy reported by the American Brachytherapy Society task force²⁰ are:

- Decrease in visual acuity
- Radiation cataract
- Intraocular radiation vasculopathy that may involve retina, optic disc and/or iris
- Brachytherapy may affect the eyelids, eye-lashes, conjunctiva, tear production, corneal surface integrity, sclera, and ocular muscles.
- Within the eye, radiation can cause iritis, uveitis, synechia, neo-vascular glaucoma, cataract, posterior neovascularization, haemorrhage, retinal detachment, retinopathy, and optic neuropathy.
- The most common late sight-limiting posterior segment complication is radiation maculopathy.
- Unusual complications include persistent strabismus and scleral thinning:

CUSTOMER SERVICE

Orders and Information

For product information or to place an order, contact Theragenics® Customer Service at (877) 444-7333 or email: customerservice@theragenics.com, Monday through Friday, 8:00 AM to 6:00 PM ET. Orders may also be submitted via facsimile at (800) 458-4303.

Returns

Defective, damaged or out of specification product may be returned for credit with prior return authorization. Please do not return product without first obtaining a return authorization.

1. Seeds

Guidelines for returning AgX100® devices to Theragenics® are provided in the "Returned AgX100® Packing List" received with your order. Appropriate labeling and shipping containers will be provided if necessary. Please indicate your request when calling for return authorization.

2. Packaging

If you desire to return lead packaging materials, please do the following:

- Contact Customer Service for return authorization.
- To ensure personnel safety, please remove all radioactive sources from the lead packaging.
- Place packaging materials in a shipping container and return to Theragenics®.

REPORTING REQUIREMENTS

All serious incidents are required to be reported as soon as possible to Theragenics® Corporation or the distributor. US phone number 1-770-831-5225 or email: customerservice@theragenics.com

REFERENCES

- Protection Against Radiation from Brachytherapy Sources. NCRP Report No. 40. Washington, D.C. (1972)
- Specification of Gamma-Ray Brachytherapy Sources. NCRP Report No. 41. Washington, D.C. (1974)
- Radiation Protection for Medical and Allied Health Personnel. NCRP Report No. 48. Washington, D.C. (1976)
- Mourtada F, Mikell J, Ibbott G. Monte Carlo calculations of AAPM Task Group Report No. 43 dosimetry parameters for the (125)I I-Seed AgX100 source model. Brachytherapy 2012; 11: 237-244.
- Chen Z, Bongiorno P, Nath R. Experimental characterization of the dosimetric properties of a newly designed I-Seed model AgX100 (1)(2)(5) interstitial brachytherapy source. Brachytherapy 2012; 11: 476-482.
- Rivard MJ, Coursey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004; 31: 633-674.
- Salembier C, Lavagnini P, Nickers P, et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007; 83: 3-10.
- Davis BJ, Horwitz EM, Lee WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012; 11: 6-19.
- Tapen FM, Blasko JC, Grimm PD, et al. Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998; 42: 1063-1067.
- Al-Qaisieh B, Carey B, Ash D, Bottomley D. The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. Int J Radiat Oncol Biol Phys 2004; 59: 397-399.
- Langley SEM, Soares R, Uribe J, et al. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer. BJU Int 2018; 121: 38-45.
- Keyes M, Miller S, Pickles T, et al. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals. Int J Radiat Oncol Biol Phys 2014; 90: 570-578.
- Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2017; 98: 286-295.
- Keyes M, Spadinger I, Liu M, et al. Rectal toxicity and rectal dosimetry in low-dose-rate (125) I permanent prostate implants: a long-term study in 1006 patients. Brachytherapy 2012; 11: 199-208.
- Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 2000; 89: 2085-2091.
- Shakespeare D, Mitchell DM, Carey BM, et al. Recto-urethral fistula following brachytherapy for localized prostate cancer. Colorectal Dis 2007; 9: 328-331.
- Leong N, Pai HH, Morris WJ, et al. Rectal Ulcers and Rectoprostatic Fistulas after (125) Low Dose Rate Prostate Brachytherapy. J Urol 2016; 195: 1811-1816.
- Keyes M, Pickles T, Crook J, et al. Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy. Brachytherapy 2015; 14: 334-341.
- Mydlo JH, Lebed B. Does brachytherapy of the prostate affect sperm quality and/or fertility in younger men? Scand J Urol Nephrol 2004; 38: 221-224.
- American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address pec, Committee AO. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13: 1-14.